Pharma BD Deal Intelligence
A stock-for-stock deal that destroyed nearly all its value within a year: Sequenom wrote off $116.9M in goodwill on Gemini Genomics in January 2002, then took the remaining $25M write-off in October 2002, effectively erasing the entire $238M deal. The combined drug-discovery unit, Sequenom Pharmaceuticals, was shuttered by July 2004.
Total loss: entire deal value written off within a year, business unit shuttered by 2004
Full analysis, sources & comparables →Announcement: all-share merger (0.2 Sequenom share per Gemini share) intended to accelerate identification of disease-associated genes; CEO Tony Schuh: 'We…
Gemini Genomics' UK-based clinical-genetics business was acquired by Sequenom in a stock deal originally valued near $238M to expand drug-development and…
Nature Biotechnology ('Sequenom steps toward drug development') frames the Gemini Genomics merger as Sequenom moving up the value chain from genotyping toward…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Stock-for-stock announced 2001-05-29, closed 2001-09. Genotyping/SNP platform plus clinical genetics. Final value ~$238M at announce.
Total loss: entire deal value written off within a year, business unit shuttered by 2004
Assessment window: 15yr post-close.
SNP genotyping and clinical-genetics association studies were the dominant precision-medicine paradigm in 2001 — using high-throughput SNP platforms to link DNA variants to disease phenotypes for drug-target discovery. The platform powered both research-tool revenue and biotech drug-discovery aspirations.
In 2001, SNP-genotyping was contested by Sequenom's MassARRAY (mass-spectrometry primer extension), Affymetrix GeneChip arrays, Applied Biosystems' TaqMan, Illumina's emerging BeadArray platform, and Orchid BioSciences. Clinical-genetics cohort companies — Gemini Genomics, deCODE Genetics (Iceland), and Genaissance Pharmaceuticals — competed for the disease-association turf. The May 2001 stock-for-stock combination, valued at ~$238M at announce and closed September 20, 2001, paired Sequenom's MassARRAY platform with Gemini's UK-based clinical-genetics cohorts to create two business units: Sequenom Genomics (MassARRAY tool sales) and Sequenom Biotherapeutics (target discovery + Gemini's clinical-genetics operations). The strategic thesis — bundling discovery-tool sales with cohort-driven drug-target work — collapsed within ~18 months as the genomics bubble deflated; Sequenom shed the Biotherapeutics unit and refocused on the MassARRAY franchise and later non-invasive prenatal testing (NIPT/MaterniT21), which ultimately became its commercial backbone before LabCorp acquired Sequenom in 2016. The Gemini Genomics deal stands as a representative casualty of the 2001 'genomics-to-drugs' M&A wave.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sequenom Inc. / Gemini Genomics plc (UK) (this deal) | 2001 | $238M | 11 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals